



15 December 2015.

### **Three-fold increase of capacity at Ales facility (LFB BIOMANUFACTURING)**

**Les Ulis, 15th December 2015 – The Ales bioproduction facility, operated by LFB BIOMANUFACTURING, specialising in cell-based manufacture of recombinant proteins and monoclonal antibodies, triples its production capacity after a first important extension in 2010.**

Resulting from major investments of the LFB group, this new three-fold increase of capacity relies mainly on the construction, qualification and commissioning of a new production unit called “UP2”. This unit covers an area of 800 square meters dedicated to production, and the building sheltering these manufacturing zones is to be achieved in september 2016. The industrial installations, equipments, and processes on the Ales facility are developed to meet the highest international standards.

UP2 is to enable the Ales site to triple its production capacity as soon as early 2017, in order to manufacture the batches of LFB’s recombinant products under development, starting with activated Factor VII currently under phase III clinical trials for a registration and launch in the USA initially. LFB’s recombinant “anti-D”, in phase II B, should also benefit from this increase in capacity as to its manufacture.

These new capacities are crucial for the production of LFB’s new medicinal products, but also for LFB BIOMANUFACTURING’s activities as a CMO (Contract Manufacturing Organisation). A company of the LFB group and operator of the Ales facility, LFB BIOMANUFACTURING has several clients for which it provides bioproduction services.